-
The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs
Sunday, August 16, 2020 - 8:30am | 807Read More...Biotech stocks came under pressure in the week ended Aug. 14 amid mixed earnings news flow from the sector. FDA decisions scheduled for the week also produced adverse outcomes. Eagle Pharmaceuticals Inc (NASDAQ: EGRX) and Fennec Pharmaceuticals Inc (NASDAQ: FENC) received complete response letters...
-
Fintech Focus For August 11, 2020
Monday, August 10, 2020 - 6:14pm | 2346Read More...Daily Perspective: The definition of market prices is whatever the Fed says it will be. - Minerd Fintech Movers: The Federal Reserve recently announced the FedNow Service, which it said will be rolled out in a phased approach, with a target service date of 2023 or 2024. - Benzinga Coinbase hires...
-
Fintech Focus For July 9, 2020
Thursday, July 9, 2020 - 10:15am | 2011Read More...Daily Perspective: We are now better at living with the virus. - Deutsche Bank Fintech Movers: The bro influencers of TikTok, released into the wild with sick iPhone hacks and dropshipping tips but a few years ago, have matured from pups to the Wolves of Social Media. Now they’re harnessing...
-
Fintech Focus For June 30, 2020
Tuesday, June 30, 2020 - 9:37am | 1683Read More...Daily Perspective: If life were predictable it would cease to be life, and be without flavor. - Eleanor Roosevelt Fintech Movers: Uber Technologies Inc.’s financial services leader Peter Hazlehurst is calling it quits as the ride-hailing giant focuses on rides and food delivery, and ices...
-
Here's A Bullish Options Play On Gilead
Tuesday, May 12, 2020 - 2:28pm | 512Read More...With the markets in turmoil over the coronavirus, no stock has embodied the unpredictability of today more than Gilead Sciences (NASDAQ: GILD). Thanks to its antiviral drug Remdesivir, which has been granted emergency use authorization by the FDA for treading COVID-19, traders have made the...
-
As Gilead's Outlook Dims, Argus Downgrades
Monday, November 13, 2017 - 11:15am | 554Read More...Biotech stocks are given to high volatility, given several risks confronting the sector, namely FDA decisions, clinical trial results, competitive pressure and drugs falling off patents. Gilead Sciences, Inc. (NASDAQ: GILD) — which has made a name for itself in the HIV and hepatitis C...
-
Gilead's Q1 Fails To Impress, But Strength Of Pipeline Not Reflected In Current Share Price
Wednesday, May 3, 2017 - 11:46am | 355Read More...BMO Capital Markets' M. Ian Somaiya maintained a Market Perform rating on Gilead Sciences, Inc. (NASDAQ: GILD) with a price target boosted from $75 to $76 after the company reported its first quarter results. Gilead's reported revenues of $6.5 billion fell short of the $6.66 billion...
-
In Light Of Negative Sentiment, Gilead's Q1 Results Weren't So Bad
Wednesday, May 3, 2017 - 9:10am | 385Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading lower by more than 2 percent Wednesday morning after the company's first quarter earnings and revenue fell short of what analysts were expecting. Although Gilead's numbers point to a top-and-bottom line beat, Barclays' Geoff...
-
Endeavor Funds' Jerome Dodson Defends 3 Stocks Beaten Down In 2016
Thursday, December 8, 2016 - 3:02pm | 454Read More...Jerome Dodson of Endeavor Funds spoke with Barron's about three stocks that were beaten down in 2016 and if investors should expect a turnaround in 2017. Gilead Shares of Gilead Sciences, Inc. (NASDAQ: GILD) have lost nearly 30 percent throughout 2016. Dodson pointed out that sales of Gilead's...
-
Gilead Trounces Hep C Estimates; Harvoni International Footprint Nearly Equals U.S.
Tuesday, February 2, 2016 - 6:17pm | 200Read More...Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's post-market session after the company beat Wall Street revenue and earnings estimates handily. Perhaps more importantly to some investors, Gilead reported that sales for its Hep C drugs, Harvoni and Sovaldi, totaled $4.89...
-
Gilead Hits New 52-Week Low; Here Are Two Reasons Why
Friday, January 29, 2016 - 2:32pm | 203Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) lost more than 5 percent on Friday and hit a new 52-week low of $82.41 after the company announced a change to its senior leadership. Effective March 10, 2016, Gilead's current Chairman and CEO John Martin will assume the role of Executive...
-
Gilead Sciences: Here's What A Bull And A Bear Are Saying
Wednesday, July 29, 2015 - 10:34am | 483Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading higher by more than 4 percent Wednesday after the company reported better-than-expected earnings for its second quarter. Here are opposing views of what two of Wall Street's top analysts are saying. Bank Of America: Long-Term...
-
Gilead Sciences Remains Popular Post-Earnings
Monday, May 4, 2015 - 10:44am | 553Read More...Gilead Sciences, Inc. (NASDAQ: GILD) released first quarter 2015 earnings on April 30. High revenues pointed to the success of Gilead’s blockbuster hepatitis C therapies; Sovaldi and Harvoni. Analysts had estimated that Gilead would post diluted earnings per share of $2.32 for the quarter...
-
Is Gilead Sciences About To Buy Vertex For $45 Billion?
Thursday, April 30, 2015 - 11:57am | 498Read More...Gilead Sciences, Inc. (NASDAQ: GILD) has been rolling in the money since the release of its hepatitis C drug duo, Sovaldi and Harvoni. Now investors are wondering how Gilead will put its pile of cash to work. In its Q4 earnings report, Gilead announced that its cash position had increased from...
-
Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says
Tuesday, April 21, 2015 - 12:57pm | 346Read More...In a report published Tuesday, RBC Capital Markets analyst Michael Yee commented on the increasing Street "appreciation" over the idea that Gilead Sciences, Inc. (NASDAQ: GILD) should acquire Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Yee noted that many investors are working...
